NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.61 (+0.59%)

Growth Price

Overvalued by 39.05%

Stability Price

Overvalued by 79.21%

Company Metrics

  • 13.12 P/E
  • 4.84 P/S
  • 3.18 P/B
  • 7.96 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 2.67 / 2.6% Dividend
  • 1.59M Avg. Vol.
  • 252.05B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis AG (ADR) (NYSE:NVS) Mereo BioPharma Group Ltd
Live Trading News - Jul 29, 2015
Novartis AG (ADR) (NYSE:NVS) would continue to hold a stake in the success of the three compounds which it will spin-off to Mereo BioPharma for further development.
Novartis AG (ADR) (NVS) To Acquire Spinifex
Business Finance News - Jun 29, 2015
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million - Bidness ETC
Novartis to buy privately held Spinifex for $200 mln - Proactive Investors USA & Canada
Stock Report on Novartis AG (ADR) (NYSE:NVS)
Street Report - Jun 16, 2015
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Novartis AG (NVS) Stock Soars On Heart-Failure Drug Approval
Bidness ETC - Jul 8, 2015
The US Food and Drug Administration (FDA) has approved Novartis AG's (ADR) (NYSE:NVS) new heart-failure drug, Entresto, the agency announced in a press release on Tuesday.
Technical Report on Novartis AG (ADR) (NYSE:NVS)
Street Report - Jul 2, 2015
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ... - WallStreet.org
Novartis AG (ADR) Says Cosentyx Can Be A $5 Billion Drug After New Trial Data
Bidness ETC - Jun 29, 2015
Novartis AG (ADR) (NYSE:NVS) has updated its annual sales forecast for its potential blockbuster injectable drug Cosentyx (secukinumab), after new clinical data establishes the drug's long-term benefits in treating psoriatic arthritis.
Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog - Yahoo News
Novartis AG (ADR) (NVS) Q2 Profits Eaten By Strengthening Dollar
Bidness ETC - Jul 21, 2015
Novartis AG (ADR) (NYSE:NVS) announced second-quarter financial results for fiscal'15 before the markets opened today.
Novartis AG (ADR) (NYSE:NVS) in Focus - Markets Wired
Stocks Posting A Big Cash Outflow: Novartis AG (ADR) (NYSE:NVS), Medtronic PLC ... - Wall Street Observer
Novartis AG (ADR) Expects Higher Profit Margin & Dividends This Year
Bidness ETC - Jun 19, 2015
Novartis AG (ADR) (NYSE:NVS) expects its profit margin to increase in 2015 on the back of a restructured drug portfolio and cost-cutting measures.
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets
Bidness ETC - Apr 24, 2015
Novartis AG (ADR) (NYSE:NVS) reported its first-quarter earnings yesterday which managed to beat analysts' expectations, mostly on the back of recent deals aimed at making the Swiss drug-maker smaller and more cost-effective.
Technical Insights on Novartis AG (ADR) (NYSE:NVS) - Markets Wired
Novartis Unveils an Alternative CV Treatment - Inside Trade
Novartis AG (ADR) May Have To Cough Up $3.3 Billion To Feds In Kickback Suit Fine
Bidness ETC - Jul 1, 2015
According to a federal court filing in New York on Monday, the US Department of Justice has sought almost $3.35 billion from Novartis AG (ADR) (NYSE:NVS) in a civil and damages suit, alleging that the company illegally boosted sales of two drugs using ...